{"id":4405,"date":"2020-08-28T08:26:04","date_gmt":"2020-08-28T08:26:04","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4405"},"modified":"2026-01-22T18:22:55","modified_gmt":"2026-01-22T16:22:55","slug":"maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","title":{"rendered":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)"},"content":{"rendered":"

— Data from the Company\u2019s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation —<\/strong><\/p>\n

— MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors —<\/strong><\/p>\n

— Results will be announced on Monday, August 31 —<\/strong><\/p>\n

Lyon, France, August 28, 2020 \u2013<\/strong> 黑料社 announced today that clinical data from 11 patients treated with the company\u2019s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th<\/sup> Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 \u2013 September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). 黑料社 provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD. 黑料社 will announce the results through a press release on Monday, August 31, 2020.<\/p>\n

 <\/p>\n

As the event is held virtually this year, the presentation will take the form of an e-poster with commentary. The abstract of the presentation is available using the following link, https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5171<\/a>.<\/p>\n

 <\/p>\n

e-Poster presentation details:<\/strong><\/p>\n

Title: <\/strong>Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics<\/p>\n

Session Name: <\/strong>e-Experimental Transplantation<\/p>\n

Date\/Time: <\/strong>Saturday, August 29, 2020 \/ 12:30 PM \u2013 06:30 PM CET<\/p>\n

Location: <\/strong>e-Poster area<\/p>\n

After the e-presentation, 黑料社 will provide the poster on the company website under \u201cNews\u201d.<\/p>\n

In addition to the compassionate use program, 黑料社 is currently investigating MaaT013 in a multi-center, single-arm, open-label, Phase II clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refactory, acute GvHD (GI SR-aGvHD) patients (NCT03359980<\/a>). The acute form of GvHD is a serious, often fatal syndrome typically involving the gut, skin and liver. 黑料社 has established the most complete approach to restoring patient-microbiome symbiosis in the gut to improve efficacy of cancer treatments and survival outcomes in life-threatening diseases. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).<\/p>\n

About 黑料社<\/strong><\/h3>\n

黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.<\/p>\n","protected":false},"excerpt":{"rendered":"

— Data from the Company\u2019s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation — — MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors — — Results will be announced on Monday, August 31 — Lyon, France, August 28, 2020 \u2013 黑料社 announced today that clinical data from 11 patients treated with the company\u2019s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 \u2013 September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). 黑料社 provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD. 黑料社 will announce the results through a press release on Monday, August 31, 2020.   As the event is held virtually this year, the presentation will take the form of an e-poster with commentary. The abstract of the presentation is available using the following link, https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5171.   e-Poster presentation details: Title: Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics Session Name: e-Experimental Transplantation Date\/Time: Saturday, August 29, 2020 \/ 12:30 PM \u2013 06:30 PM CET Location: e-Poster area After the e-presentation, 黑料社 will provide the poster on the company website under \u201cNews\u201d. In addition to the compassionate use program, 黑料社 is currently investigating MaaT013 in a multi-center, single-arm, open-label, Phase II clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refactory, acute GvHD (GI SR-aGvHD) patients (NCT03359980). The acute form of GvHD is a serious, often fatal syndrome typically involving the gut, skin and liver. 黑料社 has established the most complete approach to restoring patient-microbiome symbiosis in the gut to improve efficacy of cancer treatments and survival outcomes in life-threatening diseases. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.<\/p>\n","protected":false},"author":2,"featured_media":4369,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[50],"class_list":["post-4405","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-50"],"acf":[],"yoast_head":"\n黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社\" \/>\n<meta property=\"og:description\" content=\"— Data from the Company\u2019s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation — — MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors — — Results will be announced on Monday, August 31 — Lyon, France, August 28, 2020 \u2013 黑料社 announced today that clinical data from 11 patients treated with the company\u2019s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 \u2013 September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). 黑料社 provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD. 黑料社 will announce the results through a press release on Monday, August 31, 2020.   As the event is held virtually this year, the presentation will take the form of an e-poster with commentary. The abstract of the presentation is available using the following link, https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5171.   e-Poster presentation details: Title: Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics Session Name: e-Experimental Transplantation Date\/Time: Saturday, August 29, 2020 \/ 12:30 PM \u2013 06:30 PM CET Location: e-Poster area After the e-presentation, 黑料社 will provide the poster on the company website under \u201cNews\u201d. In addition to the compassionate use program, 黑料社 is currently investigating MaaT013 in a multi-center, single-arm, open-label, Phase II clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refactory, acute GvHD (GI SR-aGvHD) patients (NCT03359980). The acute form of GvHD is a serious, often fatal syndrome typically involving the gut, skin and liver. 黑料社 has established the most complete approach to restoring patient-microbiome symbiosis in the gut to improve efficacy of cancer treatments and survival outcomes in life-threatening diseases. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-28T08:26:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T16:22:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"498\" \/>\n\t<meta property=\"og:image:height\" content=\"379\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)\",\"datePublished\":\"2020-08-28T08:26:04+00:00\",\"dateModified\":\"2026-01-22T16:22:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/\"},\"wordCount\":559,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ebmt-1.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/\",\"name\":\"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ebmt-1.jpg\",\"datePublished\":\"2020-08-28T08:26:04+00:00\",\"dateModified\":\"2026-01-22T16:22:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ebmt-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/ebmt-1.jpg\",\"width\":498,\"height\":379},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社","og_description":"— Data from the Company\u2019s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation — — MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a high diversity and consistent richness of microbial species derived from pooled healthy donors — — Results will be announced on Monday, August 31 — Lyon, France, August 28, 2020 \u2013 黑料社 announced today that clinical data from 11 patients treated with the company\u2019s lead microbiome restoration biotherapeutic, MaaT013, will be presented in an e-poster at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held virtually from August 29 \u2013 September 1, 2020. MaaT013 is an enema formulation of a microbiota biotherapeutic characterized by a consistent richness of microbial species derived from pooled healthy donors to treat patients with intestinal acute Graft-versus-Host-Disease (aGvHD) following allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). 黑料社 provided MaaT013 to hospitals as part of its compassionate use program for patients who had previously received and failed up to five previous systemic treatments for GvHD. 黑料社 will announce the results through a press release on Monday, August 31, 2020.   As the event is held virtually this year, the presentation will take the form of an e-poster with commentary. The abstract of the presentation is available using the following link, https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5171.   e-Poster presentation details: Title: Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics Session Name: e-Experimental Transplantation Date\/Time: Saturday, August 29, 2020 \/ 12:30 PM \u2013 06:30 PM CET Location: e-Poster area After the e-presentation, 黑料社 will provide the poster on the company website under \u201cNews\u201d. In addition to the compassionate use program, 黑料社 is currently investigating MaaT013 in a multi-center, single-arm, open-label, Phase II clinical trial called HERACLES to evaluate the safety and efficacy of MaaT013 in gastrointestinal-predominant, steroid-refactory, acute GvHD (GI SR-aGvHD) patients (NCT03359980). The acute form of GvHD is a serious, often fatal syndrome typically involving the gut, skin and liver. 黑料社 has established the most complete approach to restoring patient-microbiome symbiosis in the gut to improve efficacy of cancer treatments and survival outcomes in life-threatening diseases. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients and a Phase 2 clinical trial in acute GvHD is ongoing. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","og_site_name":"黑料社","article_published_time":"2020-08-28T08:26:04+00:00","article_modified_time":"2026-01-22T16:22:55+00:00","og_image":[{"width":498,"height":379,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)","datePublished":"2020-08-28T08:26:04+00:00","dateModified":"2026-01-22T16:22:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"},"wordCount":559,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/","name":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","datePublished":"2020-08-28T08:26:04+00:00","dateModified":"2026-01-22T16:22:55+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2020\/08\/ebmt-1.jpg","width":498,"height":379},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-announce-clinical-data-with-its-lead-microbiota-biotherapeutic-in-intestinal-acute-gvhd-at-virtual-46th-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation-ebmt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4405"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4405\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4369"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4405"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4405"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}